INDUSTRIESCASE STUDIES
Pharmaceuticals & Healthcare
Supply continuity for sterile active pharmaceutical ingredients depends on far more than competitive pricing.
Looking to secure long-term supply while preserving stringent quality standards, a pharmaceutical manufacturer turned to Cognitud to strengthen the sourcing strategy for Ceftriaxone Sodium Sterile and Cefuroxime Sodium Sterile, reinforcing regulatory compliance and cold-chain integrity throughout the supply network.
The procurement category was constrained by a limited global supplier base, export restrictions, and strict aseptic handling requirements throughout transportation and storage. Frequent price fluctuations, coupled with the absence of long-term supply agreements, made budgeting difficult and increased exposure to market uncertainty. Procurement decisions also required careful evaluation of varying regulatory documentation, supplier qualifications, and logistics capabilities. Balancing cost optimization with sterility assurance and uninterrupted supply demanded a more structured sourcing approach than conventional price-based procurement.
The procurement category was constrained by a limited global supplier base, export restrictions, and strict aseptic handling requirements throughout transportation and storage. Frequent price fluctuations, coupled with the absence of long-term supply agreements, made budgeting difficult and increased exposure to market uncertainty. Procurement decisions also required careful evaluation of varying regulatory documentation, supplier qualifications, and logistics capabilities. Balancing cost optimization with sterility assurance and uninterrupted supply demanded a more structured sourcing approach than conventional price-based procurement.
Validated batch, sterility, cold-chain, and regulatory data were consolidated to establish a single source of information for supplier evaluation. Twelve prospective suppliers were identified through a qualification process covering GMP certification, API quality, sterility controls, cold-chain capability, regulatory compliance, commercial competitiveness, and supply reliability. Technical discussions involving procurement, R&D, quality, and shortlisted suppliers ensured product specifications were fully aligned before commercial evaluation commenced. Competitive RFIs, detailed RFP assessments, benchmarking across eight global suppliers, and structured negotiations compared supplier capability, quality systems, delivery performance, risk management, and pricing before the sourcing strategy was finalized through a competitive bidding process.
Validated batch, sterility, cold-chain, and regulatory data were consolidated to establish a single source of information for supplier evaluation. Twelve prospective suppliers were identified through a qualification process covering GMP certification, API quality, sterility controls, cold-chain capability, regulatory compliance, commercial competitiveness, and supply reliability. Technical discussions involving procurement, R&D, quality, and shortlisted suppliers ensured product specifications were fully aligned before commercial evaluation commenced. Competitive RFIs, detailed RFP assessments, benchmarking across eight global suppliers, and structured negotiations compared supplier capability, quality systems, delivery performance, risk management, and pricing before the sourcing strategy was finalized through a competitive bidding process.
The programme delivered 8% procurement savings on an annual spend of approximately US$300,000, supported by a three-year rate agreement incorporating annual price review mechanisms linked to market trends. Payment terms were extended by 30 days, improving cash-flow flexibility without affecting supply continuity. Supplier consolidation reduced the approved supplier base from four to two strategic partners, simplifying supplier management while improving governance. Flexible minimum order quantities introduced by the selected supplier also enhanced inventory planning and supply responsiveness, creating a procurement model that combined commercial stability with the stringent quality and compliance requirements of sterile pharmaceutical ingredients.
The next chapter of success starts with one conversation.
Talk to our Experts